Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Tim Cruise who wrote (12952)	2/11/1999 5:01:00 PM
From: QuietWon	Respond to of 90042

thx Andrew - IMCL - about friggin time for these guys to say at least a little - pls post your finding on the IMCL board. As u may know, some of us have been waiting for IMCL to be noticed. I've been quite vociferous on it, mentioned it this a.m. even on Tim Luke's and TM's threads. Spoke to Investor Relations a week ago, kicking their @sses, asking when they would announce IMCL's speaking at the investor conference. The reply was companies themselves don;t announce such, rather the sponsor of the event should make a press release. So we can kick Crut & Roth. IMCL is the REAL THING folks. Works on HUMANS !!!!!! They have phase II, will start phase III and now we all have the timing on an announcement from IMCL - "in a few weeks". Legally, a company cannot make a definitive statement saying entering Phase III until they have signed up the first person. I bet many ppl don't know that. 50% of a biotech's long term gain occurs from pt of entering Phase III until pt where they receive mktg approval. (source - December issue of biz or news week - forget the exact issue - sorry - that fact just stuck in my head). So, folks, we are going higher. 1. C225 -head & neck cancer about to enter Phase III. (Other areas of body in phase II) 2. BEC2 - already in phase III - another kicker to share price 3. Stem cells - working on it, too